(SPRY) ARS Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 737m USD | Total Return: -45.3% in 12m

Intranasal Epinephrine, Allergy Treatment, Nasal Sprays
Total Rating 14
Safety 21
Buy Signal -1.26
Biotechnology
Industry Rotation: -8.2
Market Cap: 737M
Avg Turnover: 13.6M
Risk 3d forecast
Volatility74.0%
VaR 5th Pctl12.7%
VaR vs Median3.71%
Reward TTM
Sharpe Ratio-0.57
Rel. Str. IBD6.9
Rel. Str. Peer Group5.8
Character TTM
Beta1.455
Beta Downside1.106
Hurst Exponent0.476
Drawdowns 3y
Max DD63.32%
CAGR/Max DD0.04
CAGR/Mean DD0.10
EPS (Earnings per Share) EPS (Earnings per Share) of SPRY over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.7, "2021-09": -0.65, "2021-12": -0.67, "2022-03": -0.7, "2022-06": -0.55, "2022-09": -0.5, "2022-12": 0.77, "2023-03": -0.16, "2023-06": -0.18, "2023-09": -0.16, "2023-12": -0.07, "2024-03": -0.11, "2024-06": -0.13, "2024-09": -0.2, "2024-12": 0.51, "2025-03": -0.35, "2025-06": -0.46, "2025-09": -0.52, "2025-12": -0.42, "2026-03": -0.61,
Last SUE: -0.50
Qual. Beats: 0
Revenue Revenue of SPRY over the last years for every Quarter: 2021-03: 2.112, 2021-06: 2.112, 2021-09: 0.528, 2021-12: 0.754, 2022-03: 0.663, 2022-06: 0.464, 2022-09: 0.189, 2022-12: -1.316, 2023-03: 0.02, 2023-06: 0.01, 2023-09: 0, 2023-12: -0.03, 2024-03: 0, 2024-06: 0.5, 2024-09: 2.068, 2024-12: 86.581, 2025-03: 7.973, 2025-06: 15.717, 2025-09: 32.501, 2025-12: 28.087, 2026-03: 22.681,
Rev. CAGR: 5200.25%
Rev. Trend: 86.3%
Last SUE: 0.02
Qual. Beats: 0

Warnings

Interest Coverage Ratio -39.3 is critical

Beneish M-Score -0.87 > -1.5 - likely earnings manipulation

Altman Z'' -5.54 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: SPRY ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. (SPRY) is a San Diego-based biopharmaceutical company focused on the development and commercialization of emergency treatments for severe (Type I) allergic reactions. The company’s primary asset, neffy, is a needle-free intranasal epinephrine delivery system designed as an alternative to traditional intramuscular injectors for anaphylaxis management.

Operating within the biotechnology sector, the company utilizes a specialized drug-delivery business model aimed at improving patient compliance and ease of use in acute care settings. The global epinephrine market is characterized by high barriers to entry due to stringent regulatory requirements for delivery device reliability and rapid absorption kinetics.

Investors can examine the detailed financial health and pipeline progress of this firm on ValueRay. ARS Pharmaceuticals continues to navigate the transition from a clinical-stage entity to a commercial organization as it seeks international regulatory approvals for its nasal spray technology.

Headlines to Watch Out For
  • FDA approval and commercial launch of neffy intranasal epinephrine drive revenue growth
  • Market penetration against traditional auto-injectors determines long-term market share
  • Regulatory expansion into pediatric and international markets scales global sales potential
  • Supply chain stability and manufacturing costs impact gross profit margins
  • Competition from generic and alternative needle-free delivery systems creates pricing pressure
Piotroski VR‑10 (Strict) 1.5
Net Income: -198.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.61 > 0.02 and ΔFCF/TA -54.53 > 1.0
NWC/Revenue: 197.6% < 20% (prev 284.4%; Δ -86.80% < -1%)
CFO/TA -0.61 > 3% & CFO -175.1m > Net Income -198.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.94 > 1.5 & < 3
Outstanding Shares: last quarter (99.3m) vs 12m ago 1.26% < -2%
Gross Margin: 77.10% > 18% (prev 0.92%; Δ 7.62k% > 0.5%)
Asset Turnover: 32.20% > 50% (prev 29.67%; Δ 2.52% > 0%)
Interest Coverage Ratio: -39.29 > 6 (EBITDA TTM -194.6m / Interest Expense TTM 5.04m)
Altman Z'' -5.54
A: 0.68 (Total Current Assets 245.2m - Total Current Liabilities 49.6m) / Total Assets 287.6m
B: -1.24 (Retained Earnings -355.2m / Total Assets 287.6m)
C: -0.64 (EBIT TTM -198.0m / Avg Total Assets 307.4m)
D: -1.57 (Book Value of Equity -355.3m / Total Liabilities 226.3m)
Altman-Z'' = -5.54 = D
Beneish M -0.87
DSRI: 2.74 (Receivables 28.7m/10.3m, Revenue 99.0m/97.1m)
GMI: 1.19 (GM 77.10% / 91.69%)
AQI: 2.04 (AQ_t 0.14 / AQ_t-1 0.07)
SGI: 1.02 (Revenue 99.0m / 97.1m)
TATA: -0.08 (NI -198.0m - CFO -175.1m) / TA 287.6m)
Beneish M = -0.87 (Cap -4..+1) = D
What is the price of SPRY shares? As of May 23, 2026, the stock is trading at USD 8.23 with a total of 2,126,293 shares traded.
Over the past week, the price has changed by +6.94%, over one month by -5.48%, over three months by -13.79% and over the past year by -45.32%.
Is SPRY a buy, sell or hold? ARS Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy SPRY.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SPRY price?
Analysts Target Price 25.6 211.1%
ARS Pharmaceuticals (SPRY) - Fundamental Data Overview as of 19 May 2026
P/S = 7.4486
P/B = 7.5959
Revenue TTM = 99.0m USD
EBIT TTM = -198.0m USD
EBITDA TTM = -194.6m USD
Long Term Debt = 96.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 592k USD (from shortTermDebt, last quarter)
Debt = 98.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.53m
Net Debt = -102.3m USD (calculated: Debt 98.6m - CCE 201.0m)
Enterprise Value = 635.0m USD (737.3m + Debt 98.6m - CCE 201.0m)
Interest Coverage Ratio = -39.29 (Ebit TTM -198.0m / Interest Expense TTM 5.04m)
EV/FCF = -3.62x (Enterprise Value 635.0m / FCF TTM -175.3m)
FCF Yield = -27.61% (FCF TTM -175.3m / Enterprise Value 635.0m)
 FCF Margin = -177.1% (FCF TTM -175.3m / Revenue TTM 99.0m)
 Net Margin = -200.0% (Net Income TTM -198.0m / Revenue TTM 99.0m)
 Gross Margin = 77.10% ((Revenue TTM 99.0m - Cost of Revenue TTM 22.7m) / Revenue TTM)
Gross Margin QoQ = 72.29% (prev 88.60%)
Tobins Q-Ratio = 2.21 (Enterprise Value 635.0m / Total Assets 287.6m)
Interest Expense / Debt = 2.47% (Interest Expense 2.44m / Debt 98.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -156.5m (EBIT -198.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.94 (Total Current Assets 245.2m / Total Current Liabilities 49.6m)
Debt / Equity = 1.61 (Debt 98.6m / totalStockholderEquity, last quarter 61.3m)
 Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -102.3m / EBITDA -194.6m)
 Debt / FCF = 0.58 (negative FCF - burning cash) (Net Debt -102.3m / FCF TTM -175.3m)
 Total Stockholder Equity = 128.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -64.39% (Net Income -198.0m / Total Assets 287.6m)
RoE = -40.90% (Net Income TTM -198.0m / Total Stockholder Equity 484.1m)
RoCE = -34.12% (EBIT -198.0m / Capital Employed (Equity 484.1m + L.T.Debt 96.4m))
 RoIC = -416.3% (out of range, set to none) (NOPAT -156.5m / Invested Capital 37.6m)
 WACC = 10.02% (E(737.3m)/V(836.0m) * Re(11.10%) + D(98.6m)/V(836.0m) * Rd(2.47%) * (1-Tc(0.21)))
Discount Rate = 11.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 1.45%
 [DCF] Fair Price = unknown (Cash Flow -175.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.50 | # QB: 0
Revenue Correlation: 86.30 | Revenue CAGR: 5.20k% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.53 | Chg30d=-23.26% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=-38.95% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.76 | Chg30d=-12.28% | Revisions=-20% | GrowthEPS=-1.1% | GrowthRev=+77.0%
EPS next Year (2027-12-31): EPS=-0.95 | Chg30d=-25.74% | Revisions=-20% | GrowthEPS=+45.9% | GrowthRev=+83.9%
[Analyst] Revisions Ratio: -20%